Pharmacogenomics : Social, Ethical, and Clinical Dimensions

個数:

Pharmacogenomics : Social, Ethical, and Clinical Dimensions

  • 提携先の海外書籍取次会社に在庫がございます。通常3週間で発送いたします。
    重要ご説明事項
    1. 納期遅延や、ご入手不能となる場合が若干ございます。
    2. 複数冊ご注文の場合、分割発送となる場合がございます。
    3. 美品のご指定は承りかねます。
  • 【重要:入荷遅延について】
    ウクライナ情勢悪化・新型コロナウィルス感染拡大により、洋書・洋古書の入荷が不安定になっています。詳しくはこちらをご確認ください。
    海外からのお取り寄せの場合、弊社サイト内で表示している標準的な納期よりもお届けまでに日数がかかる見込みでございます。
    申し訳ございませんが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • 製本 Hardcover:ハードカバー版/ページ数 368 p.
  • 言語 ENG
  • 商品コード 9780471227694
  • DDC分類 615.7

Full Description

Through analyses of the complex underlying issues, this interdisciplinary volume frames the agenda for dealing with genetic variation and incorporating pharmacogenomics into health care. The three sections of this book, Research Issues, Clinical Issues, and Social Perspectives address key elements integral to a comprehensive discussion of this emerging field. This groundbreaking text...* Examines new research strategies, methodologies, and ethical and social considerations of pharmacogenomics* Addresses practical considerations of anticipated changes in education, training, oversight, guidelines and protocols, and continuing education requirements* Provides analyses of the potential enormous impact of pharmacogenomics, such as in the standard of care and treatment, including perspectives from the fields of anthropology, law, ethics, and economics

Contents

Foreword (F. Collins). Preface. PART I: INTRODUCTION: SCIENCE AND SOCIETY. Public Attitudes About Pharmacogenomics (M. Rothstein, et al.). Pharmacogenomics: Pharmacology and Toxicology in the Genomics (H. Mohrenweiser). The Implications of Population Genetics for Pharmacogenomics (C. Hanis). PART II: RESEARCH AND DEVELOPMENT CHALLENGES AND CONSIDERATIONS. Genome Research and Minorities (H. Greely). Drug Development Strategies (P. Manasco & T. Arledge). Drug Development, Regulation, and Genetically Guided Therapy Pharmacogenomics (D. Feigal & S. Gutman). Intellectual Property and Commercial Aspects of Pharmacogenomics (A. Nunnally, et al.). PART III: CLINICAL APPLICATIONS. Integration of Pharmacogenomics into Medical Practice (G. Omenn & A. Motulsky). Clinical Utility Pharmacogenetics and Pharmacogenomics (N. Holtzman). Medical Liability for Pharmacogenomics (L. Palmer). The Challenges of Pharmacogenomics for Pharmacy Education, Practice, and Regulation (D. Brushwood). PART IV: THE SOCIAL DIMENSION. Economic Implications of Pharmacogenomics (C. Reeder & W. Dickson). Pharmacogenomics and the Social Construction of Identity (M. Foster). Pharmacogenomics: Considerations for Communities of Color (L. Nsiah-Jefferson). Constitutional Issues in the Use of Pharmacogenomic Variations Associated with Race (J. Robertson). PART V: EPILOGUE: POLICY PRESCRIPTIONS (M. Rothstein). Pharmacogenomics and Minority Populations: General Population Survey Questionnaire (M. Rothstein). Index.